Condition
Pain Crisis
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.6% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Terminated1
Not Yet Recruiting1
Recruiting1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT00081523RecruitingPrimary
Natural History of Sickle Cell Disease
NCT07799571Phase 1Not Yet Recruiting
Buprenorphine for the Management of Pain in Children With Sickle Cell Disease
NCT02433158Phase 3Terminated
Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
NCT01119833Phase 2Completed
Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis
Showing all 4 trials